Table 1. Features and applications of givosiran.

Alternative names	Givlaari™
Mechanism of action	small interfering RNA (siRNA); targeting ALAS1 mRNA
Indications	AHP in adults and adolescents 12 years and older
Posology and method of administration	2.5 mg/kg , once monthly, subcutaneous injection
Interaction with other medicines	CYP1A2 Theophylline; caffeine CYP2D6 Pain management (opioid , NSAIDs, and triptan) Antidepressants (TCAs, SSRIs, and SNRIs) Antipsychotics
Adverse reactions	Hypersensitivity, nausea, rash, elevated transaminase, fatigue, decreased eGFR, injection site reactions
Dose modification for adverse reactions	1.25 mg/kg dose per month
Fertility, pregnancy, and lactation	Uncertain